Study group | Mean difference CD4 | SD | R2 | y | Intercept | 95% CI |
---|---|---|---|---|---|---|
All (N = 150) | 1.21 | 20.40 | 0.991 | 0.998x + 1.807 | 1.807 | -5.09 to 8.70 |
Subtype C drug resistance (N = 58) | 2.40 | 18.11 | 0.987 | 1.0009x + 1.951 | 1.951 | -15.46 to 19.36 |
Duke ART (N = 27) | -2.04 | 18.88 | 0.980 | 0.9628x + 15.708 | 15.708 | -6.51 to 37.92 |
Kaposi Sarcoma ART (N = 65) | -0.18 | 15.77 | 0.994 | 0.9949x + 1.432 | 1.432 | -5.83 to 8.70 |
Range of CD4 + T-lymphocytes | Mean difference CD4 | SD | R 2 | y | Intercept | 95% CI |
0–250 CD4+ cells/μL (N = 40) | 2.60 | 11.94 | 0.967 | 0.9653x + 3.022 | 3.0216 | -7.25 to 13.30 |
251–500 CD4+ cells/μL (N = 69) | 0.96 | 19.59 | 0.898 | 0.9275x + 25.443 | 25.443 | -2.64 to 53.53 |
501–1200 CD4+ cells/μL (N = 41) | 0.29 | 27.49 | 0.968 | 0.9456x + 37.090 | 37.090 | -2.04 to 76.24 |